Onconetix Reports Officer/Director Changes & Comp Arrangements
Ticker: ONCO · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1782107
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Onconetix just reported leadership changes and new executive pay, watch for strategic shifts.**
AI Summary
Onconetix, Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 17, 2024, related to the departure or election of directors/officers and their compensatory arrangements. This filing also includes financial statements and exhibits. For investors, this matters because changes in leadership and executive compensation can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.
Why It Matters
Changes in leadership and executive compensation can significantly influence a company's strategic direction and financial stability, directly affecting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future company direction, which carries a moderate level of risk for investors.
Analyst Insight
A smart investor would monitor subsequent filings or press releases from Onconetix, Inc. for specific details regarding the personnel changes and compensation structures, as these details will clarify the strategic implications.
Key Players & Entities
- Onconetix, Inc. (company) — registrant filing the 8-K
- January 17, 2024 (date) — date of the earliest event reported
- January 19, 2024 (date) — date the 8-K was filed
- Blue Water Biotech, Inc. (company) — former name of Onconetix, Inc.
- Blue Water Vaccines Inc. (company) — former name of Onconetix, Inc.
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 17, 2024.
What specific items are covered in this 8-K filing by Onconetix, Inc.?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits'.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 19, 2024.
What is the current name of the registrant and what were its previous names?
The current name of the registrant is Onconetix, Inc. Its former names were Blue Water Biotech, Inc. (changed on 20230424) and Blue Water Vaccines Inc. (changed on 20190710).
What is Onconetix, Inc.'s business address and phone number?
Onconetix, Inc.'s business address is 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202, and its telephone number is (513) 620-4101.
Filing Stats: 599 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-19 16:05:40
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
- $27,083 — receive a monthly fee of approximately $27,083. The foregoing descriptions of the Sep
Filing Documents
- ea191886-8k_onconetix.htm (8-K) — 28KB
- ea191886ex10-1_onconetix.htm (EX-10.1) — 175KB
- ea191886ex10-2_onconetix.htm (EX-10.2) — 37KB
- 0001213900-24-004855.txt ( ) — 471KB
- onco-20240117.xsd (EX-101.SCH) — 3KB
- onco-20240117_lab.xml (EX-101.LAB) — 33KB
- onco-20240117_pre.xml (EX-101.PRE) — 22KB
- ea191886-8k_onconetix_htm.xml (XML) — 3KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 28, 2023, Erin Henderson resigned as Chief Business Officer of Onconetix, Inc. (the "Company"), effective as of December 21, 2023. On January 17, 2024, the Company entered into a Separation Agreement and General Release (the "Separation Agreement") with Ms. Henderson, pursuant to which the Company agreed to engage The Aetos Group, a management consulting company founded and managed by Ms. Henderson ("Aetos"), to perform certain consulting services for the Company. On January 17, 2024, the Company entered into a Consulting Agreement (the "Consulting Agreement") with Aetos, pursuant to which Aetos will provide consulting services to the Company until April 25, 2024 and receive a monthly fee of approximately $27,083. The foregoing descriptions of the Separation Agreement and Consulting Agreement are qualified in their entirety by reference to the full text of the Separation Agreement and Consulting Agreement, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 10.1 Separation Agreement, dated January 17, 2024, between the Company and Erin Henderson. 10.2 Consulting Agreement, dated January 17, 2024, between the Company and The Aetos Group. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Onconetix, Inc. Date: January 19, 2024 By: /s/ Bruce Harmon Bruce Harmon Chief Financial Officer 2